Vaccine-induced Immunity in Immunocompromised Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Cologne

About this trial

Managing respiratory virus infections in immunocompromised patients requires a multidisciplinary approach, including vaccination, though its effectiveness is often suboptimal in these individuals.

In hematological patients, poor humoral immunogenicity is common, especially when the B cell axis is affected by disease or treatment, while T cell responses may offer better protection. Current immunologic data on these patients is limited, focusing mostly on serologic parameters. To address this, we will conduct an observational study analyzing early and late booster vaccinations, with a focus on virus-specific T cell responses in vaccinated patients.

Eligibility criteria

Qualifiers

Signed informed consent form

Patients with immunosuppression either by treatment or underlying diseases

Patients who are vaccinated or willing to be vaccinated against respiratory virus infections in ac-cordance with current recommendations

Age of 18 years or older

Disqualifiers

Patients unwilling/ineligible for vaccination under current recommendations

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators